{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:24:12Z","timestamp":1726763052959},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Probability of target attainment (PTA) analyses were conducted to support the recommended ceftolozane\/tazobactam dosing regimens, adjusted for renal function, in patients with hospital\u2010acquired\/ventilator\u2010associated bacterial pneumonia (HABP\/VABP). Previously published population pharmacokinetic models describing the disposition of ceftolozane and tazobactam in plasma and epithelial lining fluid (ELF) in patients with HABP\/VABP were used to simulate ceftolozane and tazobactam concentration\u2013time profiles in plasma and ELF over the course of 14\u00a0days. The simulations were conducted for patients with normal renal function and for patients receiving adjusted doses for mild, moderate, and severe renal impairment. PTA was calculated using established pharmacokinetic\/pharmacodynamic targets for ceftolozane and tazobactam. Across renal function groups, plasma PTA was 100% for ceftolozane and &gt;99% for tazobactam; ELF PTA was &gt;99% for ceftolozane and &gt;87% for tazobactam. These results provided support for the currently recommended ceftolozane\/tazobactam dosing regimens for HABP\/VABP, which were efficacious and well tolerated in the Ceftolozane\u2013Tazobactam Versus Meropenem for Treatment of Nosocomial Pneumonia (ASPECT\u2010NP) trial.<\/jats:p>","DOI":"10.1002\/jcph.2165","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:24:51Z","timestamp":1665069891000},"page":"352-357","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ceftolozane\/Tazobactam Probability of Target Attainment in Patients With Hospital\u2010Acquired or Ventilator\u2010Associated Bacterial Pneumonia"],"prefix":"10.1002","volume":"63","author":[{"given":"Wei","family":"Gao","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh T.","family":"Patel","sequence":"additional","affiliation":[{"name":"Cognigen Corporation Simulations Plus Company  Buffalo New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zufei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Fiedler\u2010Kelly","sequence":"additional","affiliation":[{"name":"Cognigen Corporation Simulations Plus Company  Buffalo New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Bruno","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth G.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carisa De","family":"Anda","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa\u2010Ping","family":"Feng","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083-16"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S204671"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/653053"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-10"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.851"},{"key":"e_1_2_11_9_1","unstructured":"ZERBAXA\u00ae (ceftolozane and tazobactam) for injection for intravenous use. Prescribing Information. 2019. Merck Sharp & Dohme Corp. Whitehouse Station NJ USA."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1733"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03572-14"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01580-16"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01590-12"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.566"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa049"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.11.021"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa278"},{"key":"e_1_2_11_20_1","volume-title":"Clinical and Laboratory Standards Institute","author":"Clinical and Laboratory Standards Instiute (CLSI)"},{"key":"e_1_2_11_21_1","unstructured":"European Medicines Agency.Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010use\u2010pharmacokinetics\u2010pharmacodynamics\u2010development\u2010antimicrobial\u2010medicinal\u2010products_en.pdf. Accessed November 19 2020."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-20"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.2165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:42:12Z","timestamp":1692362532000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/jcph.2165"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2165","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"2022-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}